bicalutamide • triptorelin • goserelin acetate • flutamide • Firmagon (degarelix) • leuprolide acetate for depot suspension • Suprefact (buserelin acetate)

2ms

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer (clinicaltrials.gov)

P3, N=239, Completed, Radiation Therapy Oncology Group | Active, not recruiting --> Completed | Trial completion date: Jun 2029 --> Sep 2025

2 months ago

Trial completion • Trial completion date

bicalutamide • triptorelin • goserelin acetate • flutamide • leuprolide acetate for depot suspension • orteronel (TAK 700) • Suprefact (buserelin acetate)

3ms

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial (clinicaltrials.gov)

P3, N=2753, Active, not recruiting, NRG Oncology | Recruiting --> Active, not recruiting

3 months ago

Enrollment closed

CD4 (CD4 Molecule)

bicalutamide • apalutamide • triptorelin • goserelin acetate • flutamide • Firmagon (degarelix) • Orgovyx (relugolix) • leuprolide acetate for depot suspension • Suprefact (buserelin acetate)

3ms

Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer (clinicaltrials.gov)

P3, N=192, Recruiting, Proton Collaborative Group | Trial primary completion date: Dec 2025 --> Dec 2027

3 months ago

Trial primary completion date

triptorelin • goserelin acetate • leuprolide acetate for depot suspension • Suprefact (buserelin acetate)

9ms

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial (clinicaltrials.gov)

P3, N=2050, Recruiting, NRG Oncology | Trial completion date: Apr 2037 --> Nov 2026 | Trial primary completion date: Apr 2032 --> Nov 2026

9 months ago

Trial completion date • Trial primary completion date

Nubeqa (darolutamide) • bicalutamide • triptorelin • goserelin acetate • flutamide • Firmagon (degarelix) • Orgovyx (relugolix) • leuprolide acetate for depot suspension • Suprefact (buserelin acetate)

almost4years

P3, N=2478, Recruiting, NRG Oncology | Suspended --> Recruiting | Trial completion date: Dec 2038 --> Dec 2033

almost 4 years ago

Enrollment open • Trial completion date

CD4 (CD4 Molecule)

bicalutamide • apalutamide • triptorelin • goserelin acetate • flutamide • Firmagon (degarelix) • leuprolide acetate for depot suspension • Suprefact (buserelin acetate)